Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04609085 · ClinicalTrials.gov registry record

SARS-COV2 Pandemic Serosurvey in a Rare Disease Population

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
730
Enrollment target

NCT04609085 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 730 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04609085 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
730 participants
Enrollment target

Study Summary

Background: The SARS-COV2 outbreak has had a major impact on the economy and society. Researchers want to learn how widespread the infection is in the rare disease community. To do this, they will get blood samples from people with rare diseases. They will use at-home sampling. This will allow them to get samples from people across a wide area. Objective: To estimate the proportion of people with rare diseases who have SARS-COV2 antibodies in the National Center for the Advancement of Translational Sciences Rare Disease Clinical Research Network (RDCRN) Rare Diseases Survey over time. Eligibility: People under age 90 who have a rare disease and have taken part in the Cincinnati Children s Hospital Medical Center (CCHMC) protocol# 2020-0299. Design: RDCRN will tell CCHMC participants about this NIH study. RDCRN will only reach out to those who agreed to be contacted for future studies. They will be contacted by phone and email. Participants will have a virtual visit to collect data. It will take place over the phone. Participants will be sent a home kit to collect a blood sample. The kit contains gauze, a lancet, bandages, a collection device, and instructions. They will also be given shipping materials. They will give up to 80ul of blood. They will ship the sample back to NIH. Participants will complete a survey. It can be done online or over the phone. Participation will last for 1 week....

Trial Details

FieldValue
Enrollment Target 730 participants
Start Date 2021-04-19
Est. Completion 2022-06-08

What the Registry Record Tells You About NCT04609085

The ClinicalTrials.gov registry entry for NCT04609085 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04609085 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04609085 about?

NCT04609085 is a clinical study titled "SARS-COV2 Pandemic Serosurvey in a Rare Disease Population". Background: The SARS-COV2 outbreak has had a major impact on the economy and society. Researchers want to learn how widespread the infection is in the rare disease community. To do this, they will get blood samples from people with rare diseases. They will use at-home sampling. This will allow them...

What is the current status of trial NCT04609085?

This trial is currently completed. The enrollment target is 730 participants. The study started on 2021-04-19. Estimated completion is 2022-06-08.

Who is sponsoring clinical trial NCT04609085?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.